TY - JOUR
T1 - Outcomes of hepatitis C-positive kidney transplant recipients compared with hepatitis C-negative recipients in today’s era of immunosuppression
T2 - A UNOS database analysis with long-term follow-up
AU - Khalil, Ali
AU - Mujtaba, Muhammed A.
AU - Aljanabi, Omar T.
AU - Ghabril, Marwan S.
AU - Taber, Tim E.
AU - Yaqub, Muhammed S.
AU - Sharfuddin, Asif
N1 - Publisher Copyright:
© Başkent University 2017 Printed in Turkey. All Rights Reserved.
PY - 2017/6
Y1 - 2017/6
N2 - Objectives: Our objective was to study the outcomes of hepatitis C-positive renal transplant recipients compared with hepatitis C-negative renal transplant recipients. Materials and Methods: We reviewed the outcomes of hepatitis C-positive kidney transplant recipients compared with hepatitis C virus-negative recipients from the United Network for Organ Sharing/Organ Procurement and Transplantation Network database for transplants from 2000 to 2004 with follow-up until 2012. Of 61 775 recipients, 3334 were hepatitis C positive at time of transplant. Results: Hepatitis C-positive recipient status was significantly associated with male gender (70.1% vs 58.6%), deceased donor type (73.9% vs 56.6%), African American race (55.7% vs 26.8%), recipient age, increased duration of pretransplant dialysis (mean 724 days vs 624), previous transplant (19.4% vs 11.5%), donor hepatitis C positivity, delayed graft function (23.9% vs 16.0%), and all-cause hospitalizations. All-cause unadjusted, death-censored graft survival and patient survival were all significantly lower in hepatitis C-positive recipients (P <.0001). One-year acute rejection rates were higher in the hepatitis C-positive group (17.2% vs 14.6%; P =.001). Within the hepatitis C-positive group, graft survival was inferior for those who received a hepatitis C-positive donor kidney compared with a hepatitis C-negative donor kidney and those who received a deceased-donor kidney as compared with a living-donor kidney. In multivariate and Cox regression analyses, the adjusted hazard ratio for graft failure for hepatitis C positive was 1.34 (P <.001, 95% confidence interval, 1.31-1.37). Conclusions: Even in today’s era, this updated analysis still shows major inferior outcomes in hepatitis C-positive transplant recipients. Hence, aggressive treatment for hepatitis C before and after should be considered.
AB - Objectives: Our objective was to study the outcomes of hepatitis C-positive renal transplant recipients compared with hepatitis C-negative renal transplant recipients. Materials and Methods: We reviewed the outcomes of hepatitis C-positive kidney transplant recipients compared with hepatitis C virus-negative recipients from the United Network for Organ Sharing/Organ Procurement and Transplantation Network database for transplants from 2000 to 2004 with follow-up until 2012. Of 61 775 recipients, 3334 were hepatitis C positive at time of transplant. Results: Hepatitis C-positive recipient status was significantly associated with male gender (70.1% vs 58.6%), deceased donor type (73.9% vs 56.6%), African American race (55.7% vs 26.8%), recipient age, increased duration of pretransplant dialysis (mean 724 days vs 624), previous transplant (19.4% vs 11.5%), donor hepatitis C positivity, delayed graft function (23.9% vs 16.0%), and all-cause hospitalizations. All-cause unadjusted, death-censored graft survival and patient survival were all significantly lower in hepatitis C-positive recipients (P <.0001). One-year acute rejection rates were higher in the hepatitis C-positive group (17.2% vs 14.6%; P =.001). Within the hepatitis C-positive group, graft survival was inferior for those who received a hepatitis C-positive donor kidney compared with a hepatitis C-negative donor kidney and those who received a deceased-donor kidney as compared with a living-donor kidney. In multivariate and Cox regression analyses, the adjusted hazard ratio for graft failure for hepatitis C positive was 1.34 (P <.001, 95% confidence interval, 1.31-1.37). Conclusions: Even in today’s era, this updated analysis still shows major inferior outcomes in hepatitis C-positive transplant recipients. Hence, aggressive treatment for hepatitis C before and after should be considered.
KW - Graft survival
KW - Hepatitis C
KW - Kidney transplant
UR - http://www.scopus.com/inward/record.url?scp=85020397655&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020397655&partnerID=8YFLogxK
U2 - 10.6002/ect.2015.0296
DO - 10.6002/ect.2015.0296
M3 - Review article
C2 - 27310008
AN - SCOPUS:85020397655
SN - 1304-0855
VL - 15
SP - 282
EP - 288
JO - Experimental and Clinical Transplantation
JF - Experimental and Clinical Transplantation
IS - 3
ER -